Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 110 of 1,261
  1. US 12016848

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  2. US 12016877

    Anticancer compositions and methods for making and using them

    The Regents of the University of California Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  3. US 12018015

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  4. US 12018074

    Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases

    CHEMOMAB LTD. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  5. US 12018252

    Methods and compositions for identifying neoantigens for use in treating cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  6. US 12018298

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  7. US 12016950

    Devices and methods for treating ear pain

    Try This First, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  8. US 12017989

    Controlled release pharmaceutical formulations

    United Therapeutics Corporation Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  9. US 12018260

    Tunable Reversirβ„’ compounds

    Alnylam Pharmaceuticals, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  10. US 12016973

    Methods and systems for augmenting immune system responses

    Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  11. US 12018045

    17-beta-hydroxywithanolides and use thereof in treating cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  12. US 12018082

    Methods and agents for treating infections

    The Regents of the University of California Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  13. US 12016835

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  14. US 12016860

    Combination therapies with Cbl-b inhibitor compounds

    NURIX THERAPEUTICS, INC. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  15. US 12016948

    Micromotors and nanomotors for gastrointestinal diagnosis and treatment applications

    The Regents of the University of California Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  16. US 12017066

    Modulation of extracellular vesicles with electrical stimulation

    Regents of the University of Minnesota Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  17. US 12018017

    Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

    Enanta Pharmaceuticals, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  18. US 12018259

    Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  19. US 12016908

    Compositions and methods for treating hemoglobinopathies

    Beam Therapeutics Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  20. US 12018081

    Photoconjugation reactions for modification of specific proteins on live cells

    The Regents of the University of Colorado, a Body Corporate Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  21. US 12016932

    Gene editing for hemophilia A with improved factor VIII expression

    CRISPR THERAPEUTICS AG Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  22. US 12018001

    Pyrimidine cyclohexenyl glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  23. US 2024197727

    SOLID DISPERSIONS COMPRISING AMORPHOUS PIMOBENDAN AND ONE OR MORE STABILIZING POLYMERS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] Β· Granted Jun 20, 2024 Β· Expires Jun 15, 2044

    granted
  24. US 12012455

    Human monoclonal antibodies specific for FLT3 and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.